LifeStance Health Group, Inc. (LFST) LifeStance Health Group, Inc. specializes in delivering outpatient mental healthcare services through its subsidiary network. The company offers a comprehensive array of mental health solutions, encompassing psychiatric evaluations and treatment, specialized psychological and neuropsychological testing, and diverse therapeutic modalities including individual, family, and group therapy sessions. The organization addresses a wide spectrum of mental health conditions, ranging from common issues like anxiety and depression to more complex challenges such as bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. Patients have access to care through various channels: virtually via its online platform or in-person at its many centers located throughout 32 states. LifeStance is dedicated to supporting individuals across all age groups, providing care for children, adolescents, adults, and the elderly. LifeStance Health Group, Inc. was founded in 2017 and its main offices are situated in Scottsdale, Arizona.
Sector: Services-Health Services
Industry: Medical - Care Facilities
LifeStance Health Group, Inc. NASDAQ:LFST Healthcare · Medical - Care Facilities
CLOSED · Nov 6 $13.77 CLOSED · Nov 6 Prev close $13.43 Close $13.77 AH close $13.97 VOL 4.93M $ Vol $68.04M RVOL 1.36x
Mkt Cap $5.24B
VOL 4.93M sh
$ Vol $68.04M
RVOL 1.36×
Press Release ● Critical
LifeStance Reports Strong Third Quarter 2026 Financial Results and Raises Full Year Outlook
LifeStance reported Q3 2026 revenue of $455.9 million, up 25% year-over-year, with net income of $22.4 million versus $1.1 million a year ago.
Adjusted EBITDA rose 70% to $68.4 million (15.0% of revenue), Center Margin grew 38% to $161.4 million, and visit volumes increased 17% to 2.7 million on an 11% larger clinician base.
Management raised full-year 2026 guidance across all metrics — revenue to $1.741B-$1.761B and Adjusted EBITDA to $242M-$250M — citing momentum in TMS and Spravato plus improving operating leverage.
The company ended the quarter with $218.8 million in cash against $255.5 million of net long-term debt, and generated $170.0 million of operating cash flow in the first nine months of 2026.
• 3d ago AI analysis › Press Release
/C O R R E C T I O N - LifeStance Health/
LifeStance Health published observational outcomes data showing 74% of esketamine patients and 61% of TMS patients achieved clinically meaningful depression-symptom reduction.
The company is expanding access to both specialty treatments for treatment-resistant depression, a population it estimates at roughly 139,000 of its adult patients — about 28% of its depression patients.
Suicidal ideation fell 85% among esketamine patients and 50% among TMS patients after treatment, per PHQ-9 tracking. The data is self-published and observational, but supports LifeStance's higher-acuity specialty services strategy.
• 10d ago AI analysis › Press Release
LifeStance to Host Third Quarter 2026 Earnings Conference Call on November 5, 2026
LifeStance Health (NASDAQ: LFST) announced it will release its third quarter 2026 earnings before market open on Thursday, November 5, 2026.
The company will host a live conference call the same day at 8:30 a.m. Eastern Time, with a webcast available via its investor relations site and a replay posted afterward.
No financial results or guidance were included; this is a scheduling notice only.
• 24d ago AI analysis › Press Release
Nearly Half of Americans Say Fear of an Unwanted Viral Moment Keeps Them from Being Themselves in Public, LifeStance Survey Finds
LifeStance Health released a survey finding that fear of an unwanted viral moment on social media is reshaping behavior and mental well-being, with 47% of Americans saying it reduces their ability to relax in public.
The impact is most pronounced among Gen Z: roughly 3 in 4 say viral-moment fears affect their enjoyment of the present moment (74%) or willingness to leave the house (72%), and about 4 in 10 report weekly effects on mood, sleep and anxiety.
The release positions therapy as a response, with 19% of respondents saying they would consider treatment; it is a brand-awareness piece supporting LifeStance's outpatient mental health business rather than a material disclosure.
• 1mo ago AI analysis › Press Release ⚠ 3
LifeStance Health Group Announces Pricing of Secondary Public Offering
LifeStance Health priced a secondary offering of 22,250,000 shares at $12.35 per share, with all shares sold by existing stockholders rather than the company.
LifeStance will receive no proceeds, but has agreed to repurchase 2,000,000 shares from the underwriter at the underwriter's cost — a repurchase conditioned on completion of the offering.
Barclays is sole underwriter; the offering and repurchase are expected to settle on or about September 11, 2026.
• 1mo ago AI analysis › Press Release ⚠ 3
LifeStance Health Group Announces Launch of Secondary Public Offering
LifeStance Health Group (Nasdaq: LFST) launched a secondary public offering of 22,250,000 shares of common stock, all sold by existing selling stockholders under a shelf registration.
The company itself is selling no shares and will receive no proceeds, so the deal adds no primary dilution to the share count.
LifeStance authorized a concurrent repurchase of 2,000,000 shares from underwriter Barclays at the same price paid to the selling stockholders, with no underwriting fee on those repurchased shares; the offering is not conditioned on the repurchase completing.
The 22.25M-share block creates near-term supply overhang, with the 2M-share buyback offsetting less than a tenth of the offering size.
• 1mo ago AI analysis › Press Release
LifeStance to Present at Upcoming Investor Conferences
LifeStance Health Group announced that management will present at the Jefferies Healthcare Services and Technology Conference on September 14 and the Morgan Stanley Healthcare Conference on September 15.
CFO Ryan McGroarty is scheduled to present at the Jefferies conference, while CEO Dave Bourdon will present at the Morgan Stanley conference.
Both presentations will be webcast live and available for replay on the LifeStance Health investor relations website.
• 2mo ago AI analysis › Press Release
LifeStance Survey Finds Women Want Mental Healthcare Built Into Perimenopause and Menopause Care
LifeStance Health released results from a survey of 1,000 women, highlighting significant awareness gaps regarding the mental health impact of perimenopause and menopause.
The study found that 33% of women were unaware these life stages can cause mental health symptoms, while 83% of those who sought therapy found it helpful.
Citing a Mayo Clinic study on the economic costs of untreated symptoms, the company reinforced its commitment to providing integrated, life-stage-specific mental healthcare.
• 2mo ago AI analysis › Press Release ● Critical
LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook
LifeStance delivered Q2 revenue of $435.4 million, up 26% year-over-year, driven by higher visit volumes and improved clinician productivity.
The company achieved positive net income of $23.6 million and generated $87.9 million in free cash flow, prompting management to raise full-year revenue and Adjusted EBITDA guidance.
Additionally, the Board approved a new $100 million share repurchase program to replace the prior authorization.
• 3mo ago AI analysis › Press Release
LifeStance to Host Second Quarter 2026 Earnings Conference Call on August 6, 2026
LifeStance Health Group announced it will release its second quarter 2026 financial results before the market opens on Thursday, August 6, 2026.
The company will host a conference call at 8:30 a.m. Eastern Time on the same day to discuss quarterly performance, accessible via dial-in or webcast.
LifeStance operates as a provider of outpatient mental healthcare across 33 states, employing over 8,300 clinicians across more than 550 centers.
• 3mo ago AI analysis › Press Release ⚠ 1
LifeStance Health Group Announces Pricing of Secondary Public Offering
LifeStance Health Group announced the pricing of a secondary public offering of 35 million shares at $8.15 per share.
The offering is being conducted by certain stockholders, who will receive all proceeds from the sale.
The company has also agreed to repurchase 6 million shares from the underwriter, conditional on the completion of the offering.
• 6mo ago AI analysis › Press Release
LifeStance Health Group Announces Launch of Secondary Public Offering
globenewswire.com • 6mo ago Press Release ● Major
LifeStance Reports First Quarter 2026 Results
LifeStance delivered strong Q1 2026 results with revenue growing 21% year-over-year to $403.5 million and net income increasing to $14.2 million.
Adjusted EBITDA rose 48% to $51.1 million, driving free cash flow of $22.3 million and expanding center margins to 33.7%.
Management raised full-year 2026 revenue guidance to $1.64 billion-$1.68 billion and increased Adjusted EBITDA expectations to $200 million-$220 million.
• 6mo ago AI analysis › Press Release
LifeStance to Present at Upcoming Investor Conferences
LifeStance Health Group announced that management will present at two upcoming investor conferences in May and June.
CEO Dave Bourdon is scheduled to present at the Bank of America 2026 Healthcare Conference on May 13 and the William Blair 46th Annual Growth Stock Conference on June 4.
Both presentations will be webcast live and available for replay on the company's investor relations website.
• 6mo ago AI analysis › Press Release ● Critical
LifeStance Health Group Set to Join S&P SmallCap 600
Golden Entertainment will be removed from the S&P SmallCap 600 effective May 1, 2026.
The index deletion is driven by the pending acquisition of the company by VICI Properties and Blake Sartini, which is expected to close soon.
LifeStance Health Group is set to replace Golden Entertainment in the index upon the effective date.
• 6mo ago AI analysis › 
